Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
RLYB is expected to report earnings to rise 15.38% to -30 cents per share on March 18
Q4'24
Est.
$-0.30
Q3'24
Beat
by $0.09
Q2'24
Missed
by $0.30
Q1'24
Est.
$-0.47
Q4'23
Missed
by $0.03
The last earnings report on November 07 showed earnings per share of -25 cents, beating the estimate of -34 cents. With 60.64K shares outstanding, the current market capitalization sits at 27.42M.